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Background: Airway bacterial colonization by potentially pathogenic microorganisms occurs in
a proportion of patients with Chronic Obstructive Pulmonary Disease (COPD). It increases
airway inflammation and influences outcomes negatively. Yet, its diagnosis in clinical practice
is not straightforward. The electronic nose is a new non-invasive technology capable of distin-
guishing volatile organic compound (VOC) breath-prints in exhaled breath. We aim to explore if
an electronic nose can reliably discriminate COPD patients with and without airway bacterial
colonization.
Methods: Westudied 37 clinically stable COPDpatients (67.8 5.2 yrs, FEV1 41 10% ref.) and 13
healthy controls (62.8 5.2 yrs, FEV1 99 10% ref.). The presence of potentially pathogenic mi-
croorganisms in the airways of COPD patients (nZ 10, 27%) was determined using quantitative
bacterial cultures of protected specimen brush. VOCs breath-prints were analyzed byeumologia, Hospital de la Santa Creu i Sant Pau, C/Sant Antoni M. Claret 167, 08025 Barcelona, Spain.
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E-nose and bacterial colonization in COPD 1609discriminant analysis on principal component reduction, resulting in cross-validated accuracy
values. Area Under ReceiverOperating Characteristics (AUROC)was calculated usingmultiple lo-
gistic regression.
Results: Demographic, functional and clinical characteristics were similar in colonized and non-
colonized COPD patients but their VOC breath-prints were different (accuracy 89%, AUROC 0.92,
p > 0.0001). Likewise, VOCs breath-prints from colonized (accuracy 88%, AUROC 0.98,
p< 0.0001) and non-colonized COPD patients (accuracy 83%, AUROC 0.93, p< 0.0001) were also
different from controls.
Conclusions: An electronic nose can identify the presence of airway bacterial colonization in
clinically stable patients with COPD.
ª 2014 Elsevier Ltd. All rights reserved.Introduction bacterial colonization (nZ 10 and nZ 27, respectively), asIn about 20e50% of patients with clinically stable Chronic
Obstructive Pulmonary Disease (COPD), potentially patho-
genic microorganisms (PPM) can be isolated from their
airway secretions [1,2]. This bacterial colonization is asso-
ciated with enhanced airway inflammation [3,4] and more
frequent and severe episodes of exacerbation [5], both of
which can impact the clinical course of the disease nega-
tively and increase mortality [6,7]. A proper identification
of these patients may, therefore, be clinically relevant [8].
Sputum culture has well-known limitations to identify the
presence of bacterial airway colonization in COPD [4,9]. The
gold standard for the diagnosis of distal airway infections is
the quantitative culture of protected specimen brush (PSB)
[9,10], but its invasiveness limits its use in routine clinical
practice. The electronic nose (e-nose) is an emerging non-
invasive technology that detects volatile organic com-
pounds (VOCs) in the exhaled gas [11]. It uses an array of
sensors that react with different VOCs and generate a spe-
cific “breath-print” for each individual. The exhaled gas
contains a complexmix of VOCs that are derived from various
metabolic and inflammatory pathways in the lung [11,12].
Specific breath-prints of some respiratory diseases have
been successfully used for diagnostic screening of lung can-
cer, malignant pleural mesothelioma, asthma and chronic
obstructive pulmonary disease [13e16]. In addition, other
studies have demonstrated that the e-nose is also able to
identify specific upper respiratory bacterial pathogens from
in vitro cultures [17], as well as in patients with bacterial
sinusitis [18] and ventilator-associated pneumonia [19]. To
date, however, no previous study has explored the potential
utility of the e-nose to identify bacterial airway colonization
in clinically stable COPD patients, but it is conceivable that
those with PPM in their airways may have a distinct breath-
print profile than those without bacterial colonization.
Accordingly, we hypothesized that the use of an e-nose in
clinically stable COPD patients will allow identification of
patients with PPM in their airways. This pilot study sought to
explore this hypothesis.
Methods
Study design and ethics
This is a cross-sectional, descriptive and controlled study
that included COPD patients with and without airwaywell as healthy controls (nZ 13). This sample size is similar
to that of previous studies that, using the same e-nose
device and methodology used here [13e15], identified sig-
nificant differences between groups. The study protocol
was approved by the institutional review board (IIBSP-ENO-
2009-21), and all subjects signed their informed consent.
ClinicalTrials.Gov identifier: NCT01976117.
Participants
The diagnosis of COPD was established according to the
GOLD recommendations [20] and the presence airway
colonization in COPD patients by PSB (see below). All of
them were clinically stable as defined by the absence of an
exacerbation that required antibiotic or steroid treatment
within 30 days prior to inclusion. Patients receiving treat-
ment with oral steroids or other immunosuppressive agents
were excluded. Healthy controls were recruited by adver-
tisements in the hospital.
Clinical and functional characterization
Demographic data, level of current symptoms, number of
exacerbations in the previous year, time from last exacer-
bation, relevant comorbid conditions and current treat-
ments were recorded at inclusion using standardized
questionnaires. Spirometry (Datospir-500, Sibelmed SA,
Barcelona, Spain) was performed according to the Spanish
Respiratory Society (SEPAR) guidelines [21], using the pre-
dicted values for Mediterranean populations [22].
Microbiological evaluation
PSB samples were obtained from right medium lobe using a
bronchoscope and a sterile disposable microbiological brush
(ConMed, New York, NY) in all COPD patients and processed
using standard methodology [9]. In short, PSB samples were
serially diluted (1:10, 1:100, 1:1000). All microbiological
specimens were plated on blood, chocolate, Wilkins-
Chalgren and Sabouraud’s agar. The cultures were evalu-
ated for growth after 72 h. Bacterial load was considered
significant when 102 colony forming units (CFU)/ml [23].
Specific microorganims were identified according to stan-
dard methods and classified as PPM (Hemophilus influen-
zae, Streptococcus pneumoniae, Moraxella catarrhalis,
Gram negative-bacili, Pseudomonas aeruginosa and
Table 1 Demographic, clinical and functional characteristics of the three groups of subjects studied.
Colonized COPD patients
(n Z 10)
Non-colonized COPD patients
(n Z 27)
Healthy controls
(n Z 13)
Age (years) 68.1  10.9 67.8  6.9 62.8 (5.2)
Gender (M/F) 8/2 20/7 9/4
BMI (Kg/m2) 26.1  (4.0) 24.1  (5.5) 26.9  (3.1)
FEV1 postbronchodilatador (L) 1.04  0.37 1.27  0.32 2.67  0.54
FEV1 postbronchodilatador (%) pred 38  8 42  8 99  10
FEV1/FVC 0.39  0.09 0.41  0.08 0.76  0.04
GOLD-grade (II/III/IV) 0/8/2 5/18/4 NA
Current/ex-/never-smoker 4/6/0 9/18/0 5/5/0
Pack-years 43.0  8.3 48.9  13.8 16.5  15.28
ICS use 9 (90%) 27 (100%) NA
LABA use 10 (100%) 27 (100%) NA
LAMA use 9 (90%) 25 (92%) NA
Roflumilast use 1 (10%) 2 (7%) NA
2 exacerbations last year 3 (30%) 4 (15%) NA
Weeks from last exacerbation 15.0  6.2 20.7  14.5 NA
Values are mean  standard deviation. BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; LABA:
long acting beta agonists; LAMA: long acting muscarinic agonists; ICS: inhaled corticosteroids; NA: not applicable.
1610 O. Sibila et al.Staphylococcus aureus) or non-PPM (Streptococcus viridans,
Candida spp, Corynebacterium spp, and Staphylococcus
epidermidis) for analysis [24].Exhaled VOCs measurement by e-nose
To assess VOC profiles by e-nose, exhaled gas was collected
as previously described [15,16]. Exhaled gas specimens
were obtained before the bronchoscopic procedures in
COPD patients. In short, exhaled breath was collected in
10-L Tedlar bags after 3 min of tidal breathing through a
Hans Rudolph valve with an inspiratory filter and an expi-
ratory silica reservoir exposed to dry air. All participantsFigure 1 Two-dimensional principal component analyses
(PCA) plot showing the discrimination of breath-prints in
colonized COPD patients and non-colonized COPD patients
(accuracy 89%, p < 0.0001). Four samples for each subject are
displayed and connected to the class center identifier with
scatter lines to improve readability.stopped their inhaled medications, stop smoking and food-
drink intake at least 12 h before the study. The e-nose
device (Cyranose 320; Smith Detections, Pasadena, CA)
was then connected to the Tedlar bag for 5 min and changes
in the electrical resistance of its 32 organic polymeric
composite sensor array generated a breath-print VOC pro-
file in each participant. The measurement is based on a
resistance variation in each sensor when exposed to a VOC
mixture. The differential responses across the array
(resistance shifts) are presented as patterns [13e16].Data analysis
Breath-print data from COPD patients (colonized and non-
colonized) and healthy controls were compared with each
other using a pattern-recognition application built in the
MATLAB software (v.R2012a). They were represented by
logarithmic regression as mono- or bidimensional graphics
following previously published algorithms [15,16]. Raw data
were first reduced by principal component analysis (PCA) to
three principal factors. These PCA factors entered a uni-
variate ANOVA followed by post-hoc least significant dif-
ference test. Patient classification, based on these PCA
factors, was performed using a linear canonical discrimi-
nant analysis, calculated as the one that obtains the better
percentage of correctly classified patients. The discrimi-
nant function is trained with all minus one subject samples.
Then the remaining subject samples are tested. If three or
four of those samples are addressed to the true class, we
consider the subject as “well classified”. That process is
repeated for all the available subjects and the percentage
of correctly classified patients built. That method is known
as “leave-one-out” method [16]. A p value of less than 0.05
for the trained discriminant function is considered statis-
tically significant. A Receiver Operating Characteristics
(ROC) was generated using the results of the discriminant
function and combining all the samples of one subject. The
Table 2 Receiver operating characteristics analyses of breath-prints between colonized COPD patients, non-colonized COPD
patients and healthy controls.
Colonized vs. non-colonized
COPD patients
Colonized COPD
patients vs. healthy
controls
Non-colonized COPD
patients vs. healthy
controls
Cross-validation accuracy 89% 88% 83%
Sensitivity 0.82 0.80 0.81
Specificity 0.96 0.93 0.86
AUROC 0.922 0.986 0.937
Positive predictive value 0.87 0.89 0.92
Negative predictive value 0.92 0.87 0.72
AUROC: area under the receiver operating characteristic.
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curve was calculated using multiple logistic regression.
Results
Participant characterization
Thirty-seven patients with stable moderate-severe COPD
and 13 healthy controls were included in the study. PSB
cultures were positive for PPM in 10 (27%) and negative in
27 (73%) COPD patients; the former were considered colo-
nized and the latter non-colonized. H. influenzae was iso-
lated in PSB cultures in 5 patients (50%). M. catarrhalis in 2
patients (20%) and S. pneumoniae, E. coli and N. meningi-
tidis in 1 patient (10%).
Table 1 presents the principal characteristics of all
participants. Age, sex, Body Mass Index (BMI) and propor-
tion of current smokers was similar in the three groups.
Likewise, in patients with COPD, the severity of airflowFigure 2 Receiver operating characteristic (ROC) curve of
the model predicting the presence of bacterial airway coloni-
zation in COPD patients.limitation (GOLD grade), current treatment and time from
last exacerbation were similar in colonized and non-
colonized individuals, although there was a non statisti-
cally significant trend towards lower FEV1 values
(1.04 L  0.37 vs. 1.27  0.37, p Z 0.075) and higher
proportion of frequent exacerbators (2 exacerbations in
the previous year) (30% vs. 15%, p Z 0.6) in colonized
patients.
Breath-print analysis
Breath-prints from colonized vs. non-colonized COPD pa-
tients were clearly distinct on visual assessment (Fig. 1).
Canonical discriminant analysis showed a cross-validated
accuracy of 89% (p < 0.001). AUROC curve was 0.92, with
a sensitivity of 82% and a specificity of 96% (Table 2, Fig. 2).
Breath-prints corresponding to colonized COPD patients
vs. healthy controls and non-colonized COPD patients vs.
healthy controls were also fairly distinguishable (Fig. 3),
with a cross-validated accuracy of 88% (p Z <0.004),
AUROC of 0.98, sensibility of 80% and specificity of 93% for
the former, and a cross-validated accuracy of 83%
(p Z <0.001), AUROC of 0.93, sensitivity of 81% and spec-
ificity of 86% for the latter (Table 2).
When all COPD patients were considered as a single
group, irrespective of the presence of bacterial coloniza-
tion (n Z 37), COPD breath-prints could also be discrimi-
nated from healthy controls with a cross-validated accuracy
of 79% (p < 0.0001), AUROC of 0.89, sensitivity of 83% and
specificity of 76%.
Discussion
The main finding of this study is that an electronic nose can
identify accurately the presence of airway colonization by
PPM in clinically stable COPD patients.
Previous studies
It is well established that a proportion of clinically stable
patients with COPD have bacterial colonization of their
lower airways and that this is not innocuous since it is
associated with greater levels of inflammation, increased
frequency of exacerbations and an accelerate decline of
lung function [3e5,25,26]. The diagnosis of airway
Figure 3 Two-dimensional principal component analyses (PCA) plot showing the discrimination of breath-prints between (A)
colonized COPD patients and healthy controls (accuracy 88%, p < 0.0001) and (B) non-colonized COPD patients and healthy controls
(accuracy 83% p < 0.0001) along discriminative composite principal factors. Four samples for each subject are displayed and
connected to the class center identifier with scatter lines to improve readability.
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sputum culture. This method, however, has well known
limitations, including the need to produce a valid sputum
sample (not a given in many patients), the need for sample
processing and the fact that sputum largely reflects pro-
cesses occurring in the trachea and major bronchi
[4,27,28]. Alternatively, the fact that a quantitative cul-
ture of PSB, the gold standard for the diagnosis of distal
airway infections [9,10], requires bronchoscopy limits its
use in the clinic. Hence, a non-invasive, easy to use, cheap
and reliable method for the diagnosis of airway coloniza-
tion by PPM in COPD may be a valuable asset for the
management of these patients. Our results suggest that the
e-nose may fulfill these requirements.
A few previous studies have used an e-nose to identify
micro-organisms causing respiratory tract infections in a
variety of different experimental and clinical conditions.
Lai et al. demonstrated that the e-nose could distinguish
the VOCs patterns of various common respiratory pathogens
in culture, including H. influenza, S. pneumoniae and P.
aeruginosa, from control swabs [17]. Thaler et al. showed
that the e-nose identified correctly the diagnosis of bac-
terial sinusitis in 72% of the patients [18]. Finally, Hanson
et al. reported that the e-nose could effectively identify
patients with ventilator-associated pneumonia [19].
Collectively, therefore, these previous observations indi-
cate that the presence of bacteria, both in the upper and
lower respiratory tracts, produce a specific breath-print
that e-nose may detect. To our knowledge, though, our
study is the first to explore its potential utility in identifying
the presence of bacterial airway colonization in clinically
stable COPD patients.Interpretation of findings
COPD is associated with an enhanced inflammatory
response in the airways and lung parenchyma [20,29] that
persist despite smoking cessation [30]. This chronic airway
inflammation can cause a specific VOCs breath-print. Sup-
porting this possibility, two previous studies using the samee-nose we used here were able to discriminate COPD from
both asthma (accuracy 96%) and smoker controls (accuracy
66%) [16] as well as COPD from patients with non-small cell
lung cancer (accuracy 85%) [13]. Our results confirmed that
COPD breath-prints are distinct from healthy controls. More
recently Fens et al. reported that exhaled molecular pro-
files in COPD are closely associated with the types of in-
flammatory cells present, as well as with their activation
status, and suggested that breath analyses may be a novel
alternative for the assessment and monitoring of airway
inflammation in COPD [31]. Our results provide further
support to this possibility since it is well established that
the presence of bacterial colonization in some COPD pa-
tients is associated with increased airway inflammation
[3,4] and our results indicate that the VOCs pattern of COPD
patients with bacterial colonization are also different and
identifiable using an e-nose. Whether the treatment of
these patients with antibiotics influence their clinical
course is outside the scope of this study but it clearly is an
important area of future research [8].Strengths and limitations
The major strength of our study is that it tests a novel and
non-invasive diagnostic tool (e-nose), using PSB quantita-
tive cultures as the gold standard method for the diagnosis
of distal airway infection [9,10], in a population of patients
never studied before. Our results confirm, therefore, that
e-noses have the potential to be used in respiratory medi-
cine because of their easy and noninvasive use and rapid
results [32]. We acknowledge, however, that it has limita-
tions. First, since it was a pilot study that sought to explore
the feasibility and potential validity of our working hy-
pothesis, we investigated a relatively small number of pa-
tients in a single center so, despite the statistically
significant differences between groups observed here, we
think that further investigations in larger cohorts of COPD
patients in, likely, multicenter studies are warranted to
firmly confirm these promising results. Similarly, the ability
of the e-nose to identify specific bacterial species will
E-nose and bacterial colonization in COPD 1613require further studies. Second, we did not investigate the
reproducibility of results. Yet, previous studies using the
same methodology and e-nose device showed good repro-
ducibility [14,16,31]. Third, we did not identified the mo-
lecular correspondence of the different VOCs [31,33], since
this requires the use of gas chromatography and mass
spectrometry (GCeMS). It would be of great interest iden-
tify which compounds are characteristic of each group in
order to confirm these results and detect specific VOCs
related to colonized and non-colonized COPD patients.
Finally, our data analysis was limited to a discriminant
analysis approach. Future studies may use more advanced
data analysis techniques, such as Support Vector Machines
[34] or Back Propagation Neural Networks [35].
Conclusions
This pilot study shows that the e-nose may be a simple, easy
and non-invasive alternative to identify bacterial coloni-
zation in COPD patients in clinical practice.
Summary to take home
An electronic nose can identify the presence of airway
bacterial colonization in clinically stable patients with
COPD.
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